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Abstract
Background: Opportunistic illnesses still account for a huge proportion of hospitalizations and deaths among HIV-
infected patients in the post combination antiretroviral therapy (cART) era, particularly in middle- and low-income
countries. The aim of this study was to assess predictors of the top four most incident opportunistic illnesses
(tuberculosis, esophageal candidiasis, cerebral toxoplasmosis and Pneumocystis jiroveci pneumonia) in an HIV clinical
cohort from a middle-income country in the post cART era.
Methods: A total of 2835 HIV infected participants aged ≥ 18 years at enrollment were followed from January
2000 to December 2012 until the occurrence of their first opportunistic illness, death or end of study, whichever
occurred first. Extended Cox proportional hazards regression models, stratified by use of cART, were fitted to assess
predictors of opportunistic illness incidence during follow-up.
Results: The incidence rates of tuberculosis, esophageal candidiasis, cerebral toxoplasmosis and Pneumocystis
jiroveci pneumonia were 15.3, 8.6, 6.0, 4.8 per 1000 persons-year, respectively. Disease specific adjusted Cox models
showed that presence of an opportunistic illness at enrollment significantly increased disease incidence while
higher nadir CD4+ T lymphocyte count had a significant protective effect in patients not in use of cART. Duration
of cART use also significantly reduced disease incidence.
Conclusions: Our findings show that, still in the post-cART era, prevention of opportunistic infections can be
achieved by preventing immune deterioration by instituting early use of cART. Interventions focusing on early
diagnosis and linkage to care in addition to the prompt initiation of cART are essential to reduce the incidence of
opportunistic illnesses among HIV infected patients in post-cART era.
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Background
Despite the virological control and immunological re-
covery achieved with the use of combination antiretro-
viral therapy (cART), opportunistic illnesses continue to
occur at an unacceptable frequency and account for a
huge proportion of hospitalizations and deaths in HIV
infected patients in post-cART era [1–6]. Opportunistic
illnesses occurrence remains mostly related to late
presentation and linkage to care and to poor adherence
[1, 4, 7]. Late diagnosis and difficulties in access to
health care are a major challenge in the current HIV/
AIDS epidemic, and both in high- and low/middle-in-
come settings more than a third of HIV infected patients
start treatment with advanced disease [8–13]. Further-
more, poor adherence to antiretroviral therapy and
emergence of multidrug resistance are associated with
the occurrence of opportunistic illnesses in cART expe-
rienced patients [14]. In this study, we assessed the pre-
dictors of the four most incident opportunistic illnesses
in the post-cART era in an urban cohort from a middle-
income country [15].
Methods
Instituto Nacional de Infectologia Evandro Chagas (INI,
formerly known as Instituto de Pesquisa Clínica Evandro
Chagas/IPEC) is a reference center for care and treat-
ment of HIV infected patients, in Rio de Janeiro, Brazil,
since 1986. Patients included in the cohort follow
Brazilian guidelines for HIV treatment and opportunistic
infections prophylaxis [16]. Cohort procedures have
been described elsewhere [3, 17]. For this study we in-
cluded adult patients (age > =18 years) at cohort entry,
who were followed for a period of at least 60 days from
January 1st 2000 to December 31st 2012. The start of
the observation period was defined based on the first
medical appointment at INI. Follow-up ended at the
date of the first opportunistic illness for those who de-
veloped an opportunistic illness during follow-up. For
patients who never developed an opportunistic illness
during follow-up, end of follow-up was defined as the
date of death, date of last clinical visit or study closure,
whichever occurred first. Patients whose date of last
clinical visit was prior to January 1st 2012 were consid-
ered loss to follow-up. Exclusion criteria included: pa-
tients with reported intravenous drug use (n = 31 patients)
and patients with no race nor educational level informa-
tion (n = 32). Since the outcome of interest was the occur-
rence of the first opportunistic illness after cohort
enrollment, diagnoses occurring up to 30 days after the
date of cohort enrollment were considered prevalent
cases, and thus excluded from the count of incident cases.
To explore which factors were associated with the in-
cidence of the first opportunistic illness, we used ex-
tended Cox proportional hazards models accounting for
competing risks. Specifically, we evaluated the predictors
for the four most incident opportunistic illnesses in our
cohort in post-cART era, namely tuberculosis, esopha-
geal candidiasis, cerebral toxoplasmosis and Pneumocys-
tis jirovecci pneumonia (PCP) [15]. Thus, the following
endpoints were included in the model: incident cases of
tuberculosis, esophageal candidiasis, cerebral toxoplas-
mosis, PCP, and other opportunistic illnesses (those in-
cluded in Centers for Disease Control and Prevention/
CDC 1993 definition), as well as death.
The independent variables included in the models
were age, combined gender/mode of HIV acquisition
(women vs. heterosexual men vs. men who have sex with
men), race/ethnicity, educational level, presence of op-
portunistic illness at enrollment (with a +/−30 day time-
frame from the enrollment date), nadir of CD4+ T
lymphocyte count, CD4+ T lymphocyte count and HIV
viral load before end of follow up (within the 6 months
prior to), and cART use (defined as two or more nucleo-
side reverse transcriptase inhibitors plus a nonnucleoside
reverse transcriptase inhibitor or a protease inhibitor).
Demographical and clinical characteristics were com-
pared between groups using Kruskal-Wallis test for con-
tinuous variables and chi-squared for categorical variables.
Nadir CD4+ T lymphocyte count was unknown for 14
patients, the median of nadir CD4+ T lymphocyte count
distribution was used as the imputed value. Kaplan-Meier
survival curves, stratified by cART use, were plotted to
show how the survival experience varied by type of event.
Adjusted extended Cox proportional hazards regression
models included all demographic and clinical variables ex-
plored in the unadjusted models (except for last CD4+ T
lymphocyte count and last HIV viral load), since all consti-
tute potential confounding variables.
We tested the proportional hazards assumption for
each variable and globally in all final models using
Schoenfeld Residuals. We found that the proportional
hazards assumption was violated for the variable cART
use. To address this model finding, we stratified patient’s
follow up time into pre- and post-cART initiation and
explored predictors of the four most incident opportun-
istic illnesses for the two scenarios: when cART was not
used (without cART use models) and when cART was
used (with cART use models). All models were again
tested for the proportional hazards assumption and
found to not violate this assumption. In an additional
analysis, we explored the effect of last CD4+ T lympho-
cyte count and last HIV viral load in the models that
considered those who used cART. Three hundred and
eighty four patients did not have either information. In
order to not exclude them from the analysis, which have
resulted in a significant decrease in the number of
events from 60 to 39, we imputed values. For those
missing the last CD4+ T lymphocyte, the median of the
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last CD4+ T lymphocyte count distribution was used,
and for those missing the last HIV viral load a random
imputation of less than 400 copies/mm3 or 400 or more
copies/mm3 was performed. R software (version 3.0.3),
survival and mstate libraries were used for survival
models analysis.
This study was approved by the ethics committee of INI
(CAAE 0032.0.009.000–10) and was conducted according
to the principles expressed in the Declaration of Helsinki.
All patient records/information was de-identified prior to
analysis. Participants provided written informed consent.
Results
Overall, 2898 HIV infected patients aged 18 years or
more enrolled the INI cohort between January 1st 2000
and November 1st 2012 and were followed-up for at
least 60 days. After excluding 31 patients who reported
intravenous drug use and 32 patients with no race nor
educational level information, 2835 patients were in-
cluded in the present study, 566 of which developed an
opportunistic illness during follow-up (Table 1). The
study population accounted for total follow-up of 11,571
PY (mean follow-up of 4.1 years per patient). Ninety-one
(3.2 %) individuals were deemed loss to follow-up, yield-
ing a rate of loss to follow-up of 7.9/1000PY.
Tuberculosis (incidence rate [IR]: 15.3/1000 person-
years [PY]), esophageal candidiasis (IR: 8.6/1000PY),
cerebral toxoplasmosis (IR: 6.0/1000PY) and PCP (4.8/
1000PY) were the four most incident illnesses in the
period. In total, cases of tuberculosis, esophageal candid-
iasis, cerebral toxoplasmosis and PCP accounted for
71 % (402 out of 566) of the diseases. The median age at
cohort enrollment was 35.6 years (interquartile range
[IQR]: 28.7–42.7). There was a significant difference in
Table 1 Demographic and clinical characteristics of the patients in the cohort and stratified by the occurrence of specific
opportunistic illnesses
Tuberculosis Esophageal candidiasis Cerebral toxoplasmosis PCP All patientsa
N = 177 N = 100 N = 70 N = 55 N = 2835 p-value
Incidence rateb (CI 95 %) 15.3 (13.2, 17.7) 8.6 (7.1, 10.5) 6.0 (4.8, 7.6) 4.8 (367, 6.2) – <0.001
Age, median (IQR) 35.4 (28.4,41.5) 38.6 (32.6,45) 33.8 (28.1,40.9) 39.1 (29.6,45.1) 35.6 (28.7,42.7) 0.02
18–29 years (%) 50 (28.2) 15 (15) 21 (30) 13 (23.6) 750 (26.5) 0.05
30–39 years (%) 67 (37.9) 36 (36) 27 (38.6) 13 (23.6) 1035 (36.5)
40–49 years (%) 46 (26) 34 (34) 16 (22.9) 19 (34.5) 731 (25.8)
50+ years (%) 14 (7.9) 15 (15) 6 (8.6) 10 (18.2) 319 (11.3)
Gender-risk 0.21
Women 57 (32.2) 41 (41) 27 (38.6) 11 (20) 930 (32.8)
Heterossexual men 59 (33.3) 27 (27) 23 (32.9) 22 (40) 833 (29.4)
MSM 61 (34.5) 32 (32) 20 (28.6) 22 (40) 1072 (37.8)
Race/ethnicity 0.12
White (%) 73 (41.2) 40 (40) 29 (41.4) 32 (58.2) 1415 (49.9)
Non-white (%) 104 (58.8) 60 (60) 41 (58.6) 23 (41.8) 1420 (50.1)
Educational level 0.03
0–8 years (%) 117 (66.1) 66 (66) 48 (68.6) 25 (45.5) 1399 (49.3)
9+ years (%) 60 (33.9) 34 (34) 22 (31.4) 30 (54.5) 1436 (50.7)
Nadir CD4 T-cell count (cells/mm3)
Median (IQR) 107 (48,218) 74.5 (21,188.2) 63.5 (20,159.5) 55 (12,146) 196 (71,311.5) 0.002
<50 (%) 45 (25.4) 39 (39) 33 (47.1) 25 (45.5) 549 (19.4) 0.03
50–199 (%) 82 (46.3) 39 (39) 27 (38.6) 22 (40) 898 (31.7)
200–349 (%) 40 (22.6) 17 (17) 8 (11.4) 5 (9.1) 847 (29.9)
350+ (%) 10 (5.6) 5 (5) 2 (2.9) 3 (5.5) 541 (19.1)
Opportunistic illness at enrolmment 44 (24.9) 43 (43) 35 (50) 21 (38.2) 211 (7.4) <0.001
cART use during follow-up (%) 30 (16.9) 10 (10) 12 (17.1) 8 (14.5) 1878 (66.2) 0.43
Time of cART use in yearsc, median (IQR) 1.1 (0.6,2.7) 0.8 (0.4,1.3) 0.6 (0.1,1.6) 1.7 (1.1,2.1) 2.2 (0.9,4.1) 0.32
cART combination antiretroviral therapy, PCP Pneumocystis jiroveci pneumonia, HR, hazard ratio, CI confidence interval, MSM men who have sex with men
aIncludes the entire study population
bPer 1000 person-years
cFor those who used cART before end of follow-up
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the age at cohort enrollment among the groups of pa-
tients who developed each of the four diseases, with
older patients in the PCP group (18 % of patients with
50 years or more) and a younger range of patients in the
tuberculosis and the cerebral toxoplasmosis groups. One
third of the cohort patients were women, the highest
proportion of women was seen in the esophageal can-
didiasis group (41 %) in contrast with the smallest
proportion of women observed in PCP group (20 %). Al-
most half of the patients were non-white and had less
than 9 years of formal education (Table 1).
Overall, the median nadir CD4+ T lymphocyte count
of the cohort was low (196 cells/mm3, IQR: 71–312).
When comparing the groups of patients who developed
the opportunistic illnesses of interest we found that
patients who developed PCP had the lowest nadir CD4+
T lymphocyte counts (median of 55 cells/mm3 [IQR:
12–146], with 46 % of the patients having less than 50
cells/mm3), followed closely by those who developed
cerebral toxoplasmosis (median of 63 cells/mm3 [IQR:
20–160], with 47 % of the patients having less than 50
cells/mm3). Patients who developed tuberculosis had the
highest nadir CD4+ T lymphocyte (median of 107 cells/
mm3, IQR: 48–218). Overall, 66 % of the patients used
cART before end of follow-up. Compared to the entire
cohort, the use of cART was less frequent among pa-
tients that developed one of the four studied diseases.
Although not significantly different, the esophageal can-
didiasis group had the smallest proportion of cART
users (10 %) while the tuberculosis and cerebral toxo-
plasmosis groups had 17 % of cART users. As for the
duration of cART use there was no significant difference
among the groups, with the shortest time for the cere-
bral toxoplasmosis group (median: 0.6 year, IQR:0.1, 1.6)
and the longest time for PCP (median: 1.7 year, IQR: 1.1,
2.1) (Table 1).
The 2835 included patients accounted for 6509 PY not
on cART and 5062 PY on cART. The Kaplan-Meier sur-
vival curves illustrating the probability of event-free sur-
vival over follow-up time without cART (Fig. 1a) and
with cART (Fig. 1b) shows that the incidence of all four
diseases occurs more abruptly without cART than with
cART. The incidence rate of opportunistic illnesses was
significantly lower when cART was used compared to
when cART was not used (73.6/1000 PY without cART
vs. 17.2/1000 PY with cART, p < 0.001).
In the non-cART models, non-white race/ethnicity
(hazard ratio [HR] 1.47, 95 % confidence interval [95 %
CI] 1.04–2.06) and lower educational level (<9 years of
formal education) (HR 1.64, 95 % CI 1.14–2.35) were
associated with an increased hazard of tuberculosis.
Higher nadir CD4+ T lymphocyte count (per 100 cells/
mm3) was associated with significantly reduced hazard
of tuberculosis (HR 0.79, 95 % CI 0.70–0.89), esophageal
candidiasis (HR 0.74, 95 % CI 0.62–0.89), cerebral toxo-
plasmosis (HR 0.62, 95 % CI 0.48–0.81) and PCP (HR
0.58, 95 % CI 0.43–0.79). The presence of an opportun-
istic illness at enrollment was also significantly associ-
ated with an increased hazard for all four studied
illnesses (Table 2).
In the cART use models, the above described associa-
tions of non-white race and lower educational level with
increased hazard of tuberculosis were no longer ob-
served. In contrast, the presence of an opportunistic ill-
ness at enrollment still led to a significantly increased
hazard, even stronger than that observed in non-cART
models, for all studied diseases. Additionally, per year
use of cART significantly reduced the hazard of tubercu-
losis (HR 0.78, 95 % CI 0.63–0.97) and cerebral toxo-
plasmosis (HR 0.61, 95 % CI 0.39–0.96). For esophageal
candidiasis and PCP, although we had found a protective
effect of per year use of cART, the estimated effects did
not reach statistical significance (Table 3).
The additional analysis showed a significant protective
effect of higher last CD4+ T lymphocyte count on the
incidence of cerebral toxoplasmosis (HR 0.70 per 100
cell/mm3, 95 % CI 0.49–0.99, Table 4). For all other ill-
nesses, neither last CD4+ T lymphocyte count nor last
HIV viral load were significantly associated with the
incidence of opportunistic illnesses. Of note is the fact
that the addition of these variables to the model pre-
sented in Table 3 did not significantly change the effect
of the other variables.
Discussion
In this analysis, we studied the predictors of the four
most incident opportunistic illnesses in the post-cART
era in an urban cohort of HIV-infected individuals from
Rio de Janeiro, Brazil. In the non-cART models, we
showed a significant protective effect of higher nadir
CD4+ T lymphocyte count in reducing the incidence all
illnesses. When modeling the predictors of incident op-
portunistic illnesses in the presence of cART, increased
duration of cART led to a decreased incidence of all
studied illnesses. Additionally, in the models with and
without cART, we found that the presence of an oppor-
tunistic illness at cohort enrollment was strongly associ-
ated with an increased incidence of all studied illnesses.
We found that tuberculosis was the most incident
opportunistic illness, almost twice as frequent as the
second most frequent disease (incidence rates of 15.3/
1000PY vs. 8.6/1000PY of tuberculosis and esophageal
candidiasis, respectively, during the study period). In
countries with a high tuberculosis burden, as is the case
for Brazil, Rio de Janeiro in particular, HIV and tubercu-
losis co-infection represent a huge public health chal-
lenge; tuberculosis accounts for the majority of
hospitalizations and deaths in HIV infected populations
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[5, 18–20]. In the absence of cART, we observed that
proxies of poverty (i.e. non-white race/ethnicity and low
education) led to higher tuberculosis incidence, as it oc-
curs in the general population [21, 22]. Our findings
thus likely reflect the local high burden of tuberculosis
and shows how it leads to increased morbidity also for
HIV infected individuals. Additionally, and differently
from other opportunistic illnesses, tuberculosis can
occur in HIV-infected patients who may not have severe
immunodeficiency, a finding also shown in our study by
the higher median nadir CD4+ T lymphocyte count
among those who developed tuberculosis compared to
those who developed other diseases. Nonetheless, simi-
larly to data already published [19, 23], we demonstrated
that for patients not using cART, higher nadir CD4+ T
lymphocyte counts significantly reduced the incidence of
tuberculosis. Moreover, for patients who developed tu-
berculosis while in use of cART, we observed a per year
increased protection of cART use, while controlling for
CD4+ T lymphocyte count. This finding has been
Fig. 1 Kaplan-Meier survival curves illustrating the probability of event-free survival over follow-up time for patients who never used cART (top)
and for those who used cART (bottom)
Coelho et al. BMC Infectious Diseases  (2016) 16:134 Page 5 of 9
described in other settings with a high burden tuberculosis
and indicates that the early use of cART can promote
recovery of mycobacterial-specific immunity reducing the
risk of active tuberculosis [24–26]. It could be argued that
for patients using cART, the occurrence of opportunistic
illnesses can be related to inflammatory reconstitution of
the immune system (IRIS) and unmasking of previous
opportunistic illnesses, this being particularly relevant for
tuberculosis [27]. However, for our results this hypothesis
loses strain when we observe that the lower limit of the
interquartile range of duration of cART use among pa-
tients who developed tuberculosis was superior to
6 months, with median of 1.1 year, which speaks against
IRIS and unmasking tuberculosis in our study.
Table 3 Adjusted Cox hazards regression models for specific opportunistic illnesses for patients who used combination antiretroviral
therapy (N = 1878 individuals)
Tuberculosis Esophageal candidiasis Cerebral Toxoplamosis PCP
(N = 30) (N = 10) (N = 12) (N = 8)
HR (CI) HR (CI) HR (CI) HR (CI)
Gender-Risk
Women Ref. Ref. Ref. Ref.
Heterosexual men 0.85 (0.38–1.88) 0.15 (0.02–1.25) 1.46 (0.39–5.43) 0.81 (0.16–4.20)
MSM 0.53 (1.89–1.58) 0.25 (0.05–1.42) 0.31 (0.05–2.00) 0.59 (0.08–4.16)
Age (per year) 1.02 (0.99–1.06) 0.93 (0.86–1.02) 0.91 (0.84–0.99) 1.07 (1.00–1.14)
Race/ethnicity
White Ref. Ref. Ref. Ref.
Non-white 0.86 (0.39–1.88) 2.10 (0.43–10.29) 0.46 (0.14–1.51) 1.26 (0.27–5.87)
Educational level
0–8 years 2.08 (0.78–5.51) 0.89 (0.19–4.12) 1.22 (0.29–5.10) 0.38 (0.07–2.03)
9+ years Ref. Ref. Ref. Ref.
Nadir CD4+ T lymphocyte (per 100 cells/mm3) 0.85 (0.63–1.15) 0.73 (0.42–1.25) 0.89 (0.59–1.33) 1.25 (0.83–1.90)
Opportunistic illness at enrollment 23.0 (9.60–55.2) 13.6 (2.93–63.3) 34.6 (8.50–141.4) 21.5 (2.86–162.1)
Time under cART (per year) 0.78 (0.63–0.97) 0.55 (0.29–1.03) 0.61 (0.39–0.96) 0.60 (0.33–1.08)
PCP Pneumocystis jiroveci pneumonia, HR hazard ratio, CI 95 % confidence interval, MSM men who have sex with men
Bold font implies statistically significant results assuming a 5 % significance threshold
Table 2 Adjusted Cox hazards regression models for specific opportunistic illnesses for patients who did not use combination
antiretroviral therapy (n = 2750 individuals)
Tuberculosis Esophageal candidiasis Cerebral Toxoplamosis PCP
(N = 147) (N = 90) (N = 58) (N = 47)
HR (CI) HR (CI) HR (CI) HR (CI)
Gender-Risk
Women Ref. Ref. Ref. Ref.
Heterosexual men 1.29 (0.85–1.95) 0.71 (0.43–1.19) 0.67 (0.35–1.26) 2.10 (0.91–4.84)
MSM 1.45 (0.95–2.20) 1.02 (0.61–1.71) 0.89 (0.46–1.71) 1.97 (0.84–4.64)
Age (per year) 0.98 (0.96–1.00) 1.03 (1.00–1.04) 1.00 (0.97–1.03) 1.01 (0.98–1.04)
Race/ethnicity
White Ref. Ref. Ref. Ref.
Non-white 1.47 (1.04–2.06) 1.29 (0.83–2.00) 1.40 (0.80–2.45) 0.71 (0.39–1.31)
Educational level
0–8 years 1.64 (1.14–2.35) 1.41 (0.88–2.26) 1.39 (0.77–2.53) 0.71 (0.38–1.33)
9+ years Ref. Ref. Ref. Ref.
Nadir CD4+ T lymphocyte (per 100 cells/mm3) 0.79 (0.70–0.89) 0.74 (0.62–0.89) 0.62 (0.48–0.81) 0.58 (0.43–0.79)
Opportunistic illness at enrollment 1.61 (1.04–2.52) 6.27 (3.94–9.96) 5.65 (3.23–9.89) 4.10 (2.15–7.82)
PCP Pneumocystis jiroveci pneumonia, HR hazard ratio, CI 95 % confidence interval, MSM men who have sex with men
Bold font implies statistically significant results assuming a 5 % significance threshold
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In this study, we also explored the predictors of
esophageal candidiasis, cerebral toxoplasmosis and PCP
incidence and found that higher nadir CD4+ T lympho-
cyte count was highly protective among patients not
under cART. Additionally, in the models with cART,
duration of cART also decreased the incidence of all dis-
eases. The strong effect of the presence of an opportun-
istic illness at enrollment in the risk of an incident
opportunistic illness during follow-up corroborates the
vast literature attesting to the benefits of preventing im-
mune deteriorating with cART use [28–30] while also
providing an updated analysis of the predictors of inci-
dence of important opportunistic illnesses in a middle-
income country with universal use of cART.
Recently, data published from several trials showed
important results addressing early start of cART that
should modify the standard of care of HIV infected pa-
tients [24, 31, 32]. They all reported strong evidence that
early initiation of cART significantly reduces the risk of
death or AIDS-defining illness irrespective of the CD4+
T lymphocyte count. In this study, we observed that the
use of cART was associated with a 77 % incidence re-
duction and that for those patients not on cART, most
opportunistic illnesses occurred early in the follow-up
(less than 2 years). The results of the present study and
the findings from the recent publications collectively
suggest that the prompt start of cART after cohort en-
rollment could have prevented a signficant fraction of
the opportunistic illnesses. It is therefore most fortunate
that, since 2013, Brazilian guidelines have been updated
and cART is now recommended for all HIV-infected in-
dividuals [16].
On the other hand, our results showed that 80 % of
the patients had a nadir CD4+ T lymphocyte count
under 350 cells/mm3, and that low nadir CD4+ T
lymphocyte counts was associated with increased haz-
ard of opportunistic illnesses. Late HIV diagnosis and
late presentation to care persist as major challenges
in Brazil and other median/low income settings [33].
A recent meta-analysis showed that one third of the
HIV-infected population worldwide discovered their
HIV status upon hospital admission [2]. So while
early start of cART is a protective action to prevent
AIDS progression, testing and linkage to care are es-
sential to allow HIV-infected patients to benefit from
this intervention.
Table 4 Adjusted Cox hazards regression models (including last CD4 and last viral load as independent variables) for patients who
used antiretroviral therapy (N = 1878 individuals)
Tuberculosis Esophageal candidiasis Cerebral Toxoplamosis PCP
(N = 30) (N = 10) (N = 12) (N = 8)
HR (CI) HR (CI) HR (CI) HR (CI)
Gender-Risk
Women Ref. Ref. Ref. Ref.
Heterosexual men 0.82 (0.37–1.82) 0.16 (0.02–1.39) 1.10 (0.27–4.43) 0.90 (0.17–4.73)
MSM 0.49 (0.16–1.48) 0.37 (0.06–2.24) 0.34 (0.04–2.71) 0.57 (0.08–4.09)
Age (per year) 1.02 (0.98–1.06) 0.94 (0.86–1.02) 0.90 (0.82–0.99) 1.07 (1.00–1.14)
Race/ethnicity
White Ref. Ref. Ref. Ref.
Non-white 0.90 (0.41–2.00) 1.84 (0.35–9.51) 0.53 (0.14–1.92) 1.05 (0.21–5.19)
Educational level
0–8 years 1.89 (0.70–5.12) 1.05 (0.22–5.12) 1.46 (0.34–6.33) 0.44 (0.08–2.41)
9+ years Ref. Ref. Ref. Ref.
Nadir CD4+ T lymphocyte (per 100 cells/mm3) 0.88 (0.62–1.24) 0.95 (0.50–1.79) 1.17 (0.85–1.61) 1.15 (0.73–1.83)
Last CD4+ Tlymphocyteª (per/100 cells/mm3) 0.95 (0.80–1.13) 0.87 (0.61–1.23) 0.70 (0.49–0.99) 1.09 (0.90–1.33)
Last HIV viral loadb
<400 copies/mm3 Ref. Ref. Ref. Ref.
>400 copies/mm3 0.35 (0.08–1.56) 4.45 (0.98–20.19) 3.04 (0.73–12.58) 2.57 (0.42–15.88)
Opportunistic illness at enrollment 23.01 (9.44–56.09) 15.52 (3.38–71.30) 31.96 (8.31–123.88) 21.83 (2.85–167.29)
Time under cART (per year) 0.79 (0.63–0.99) 0.71 (0.40–1.28) 0.70 (0.44–1.12) 0.60 (0.33–1.08)
cART combination antiretroviral therapy, PCP Pneumocystis jiroveci pneumonia, HR hazard ratio, CI 95 % confidence interval, MSM men who have sex with men
ªData imputed for 333 individuals with missing last CD4
bData imputed for 368 individuals with missing last HIV viral load
Bold font implies statistically significant results assuming a 5 % significance threshold
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We showed that there was a significant decrease in the
incidence rates of opportunistic illnesses when cART was
used compared to when it was not. However, our findings
also show that despite this significant decrease in inci-
dence, opportunistic illnesses continue to occur in cART
experienced patients. We hypothesize that the reasons for
clinical failure and disease progression among cART expe-
rienced patients likely include poor adherence, suboptimal
response to cART and virological failure as other studies
have shown [1, 7].
There are limitations to our study that should be ac-
knowledged. First, we could not take into account the
use of prophylactic isoniazid. Isoniazid prophylaxis is
recommended by the World Health Organization in set-
tings with a high burden of tuberculosis [34]. Studies
have shown that isoniazid prophylaxis prevents tubercu-
losis [35, 36] particularly among those with positive tu-
berculin skin test (TST) [37, 38], and that this effect
extends to HIV infected patients on cART, providing a
long term protective effect [39–41]. Brazilian guidelines
recommend the use of prophylactic isoniazid for HIV in-
fected patients with reactive TST [42]. Despite formal
recommendations, both TST and prophylactic isoniazid
are still inconsistently used in Brazil, with a fraction of
patients not being prescribed prophylactic isoniazid des-
pite having a positive TST [43]. This inconsistent use
limited our ability to explore the impact of prophylactic
isoniazid on the incidence of tuberculosis, an important
limitation of the present study. In fact, this limitation ex-
tends to the use of other prophylaxis such as for PCP
and cerebral toxoplasmosis. To correctly account for
prophylaxis use we would need detailed time dependent
CD4+ T lymphocyte counts to allow us to determine
who, when and for how long prophylaxis should haven
prescribed and, among those, who in fact used it. With-
out this information, we cannot correctly compare the
groups of patients that used prophylaxis as needed, to
those that did not use despite the need, to those who
never needed prophylaxis. Second, the lack of consistent
CD4+ T lymphocyte counts at the moment of the
diagnosis of the opportunistic illnesses led us use nadir
CD4+ T lymphocyte count as a proxy of the patients’
immune status. To explore the impact of the last CD4+
T lymphocyte counts and last HIV viral load on oppor-
tunistic illnesses incidence we conducted an additional
analysis among patients who used cART and found that
they did not provide additional information while also
not modifying the effects of the variables already ex-
plored. Third, we lacked information on adherence to
cART, thus prescribed cART was considered in use until
end of follow-up. It is likely that if adherence informa-
tion was present to modulate the effect of cART an even
stronger effect would have been seen for this variable and
as such our results can be considered conservative
estimates. Finally, our cohort population is non-probabilistic
such that our findings may lack generalizability. Despite
these limitations, our clinical care setting has a well-
established and continuously updated database that pro-
vides reliable information on clinical events and deaths.
Also, our setting provides a primary and specialty care in-
cluding emergency assistance such that the patients who
care at INI resort to it in case of illnesses making clinical
events underestimation very unlikely.
Conclusion
In summary, we have shown that, in post-cART era, pre-
vention of opportunistic illnesses can be achieved by
preventing immune deterioration by instituting early use
of cART. Early HIV diagnosis and linkage to care are
important challenges for HIV primary care, without
which HIV-infected patients will not have the opportun-
ity to benefit from the protective effects of cART. Efforts
to diagnose and link HIV infected patients to primary
care need to be intensified in order to diminish HIV as-
sociated morbidity. Early initiation of cART has been
proved to be a protective intervention against AIDS pro-
gression and death, our results corroborate with these
findings and reinforce the most recent position of the
Brazilian Heath Ministry that advocates in favor of the
test and treat strategy.
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